FINANCIAL EXPRESS

Place: Mumbai

Date: 14/02/2019

21

FRIDAY, FEBRUARY 15, 2019

NYSSA CORPORATION LIMITED

CIN: L70101MH1981PLC024341

Office No.- 002, Gulmohar Complex, Opposite Anupam Cinema, Station Road, Goregaon (E), Mumbai-400 063.

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER /PERIOD ENDED 31st DECEMBER., 2018

ı	STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER /PERIOD ENDED 31st DECEMBER., 2018 (₹. in Lakhs)														
s				Stand	lalone			Consolidated							
IN	No.	(Quarter Ende	d	F	Period Ended		C	uarter Ende	d	F	Period Ended			
L		31.12.2018 Unaudited	30.09.2018 Unaudited	31.12.2017 Unaudited	31.12.2018 Unaudited	31.12.2017 Unaudited	31.03.2018 Audited	31.12.2018 Unaudited	30.09.2018 Unaudited	31.12.2017 Unaudited	31.12.2018 Unaudited	31.12.2017 Unaudited	31.03.2018 Audited		
1	1. Total Income (1+2)	154.47	270.30	37.39	456.25	74.74	179.47	169.97	330.05	53.64	623.50	442.20	601.97		
2	2. Profit /(loss) before exceptional and extraordinary items and tax	24.41	54.76	28.61	42.50	33.06	22.11	20.23	58.91	23.78	44.67	61.40	60.94		
3	3. Profit / (loss) before tax (after exceptional and extraordinary items)	24.41	54.76		42.50	33.06	22.11	20.23	58.91	23.78	44.67	61.40	60.94		
4	4. Profit /(loss) after Tax (9-10)	18.13	50.10	21.25	31.56	24.55	13.67	15.25	52.94	17.98	33.06	44.14	39.65		
5	5. Total comprehensive income	15.27	52.92	21.25	33.04	24.55	39.55	15.27	52.92	18.01	33.04	43.94	39.81		
6	6. Earning per share (Face Value of Rs. 1 Each)														
ı	a. Basic and diluted EPS before Extraordinary items for the period,														
ı	for the year to date and for the previous year (not to be annualized)	0.05	0.18	0.07	0.11	0.08	0.13	0.05	0.18	0.06	0.11	0.15	0.13		
1	b. Basic and diluted EPS after Extraordinary items for the period,														
1	for the year to date and for the previous year (not to be annualized)	0.05	0.18	0.07	0.11	0.08	0.13	0.05	0.18	0.06	0.11	0.15	0.13		

The above is an extract of the detailed format of Quarterly/Half year Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Half year Financial Results are available on the websites of the Bombay Stock Exchange(s) and the company. (www.bseindia.com and www.nyssacorporationltd.com)

Standalone (Ind AS)

BY BOARD OF DIRECTOR FOR NYSSA CORPORATION LTD DIRECTOR

> PRASANNA YADAV SHIRKE DIN: 07654053

DUCON

Standards) Rules 2015, as amended.

Thane 14-Feb-19

DUCON INFRATECHNOLOGIES LIMITED

Regd. Office: Ducon House, Plot No. A/4, Road No. 1, MIDC, Wagle Industrial Estate, Thane 400604 CIN No: L72900MH2009PLC191412 Web site: www.duconinfra.co.in Contact no.022-41122115

Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2018

		100				- 133	(RS III lakiis)
Г			Quarte Ende	d	Nine Mont	Year ended	
	Particulars	December 31, 2018	September 30, 2018	December 31, 2017	December 31, 2018	December 31, 2017	31.03.2018
1.	Total Income from Operations (net)	9,305.20	10,352.84	10,011.13	29,603.03	28,568.25	41,500.24
2.	Net Profit after taxes and minority interest	81.49	165.06	13.06	561.16	221.48	233.29
3.	Net Profit after tax & minority interest (after Extraordinary items)	81.49	160.07	13.06	551.18	215.55	228.52
4.	Equity Share Capital (Face Value Rs.10/- each)	1,046.75	1,046.75	784.23	1,046.75	784.23	784.23
5.	Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of the previous year	-	-	-		-	6440.04
6.	Earnings Per Share (before extraordinary items)	-	-	-	-	-	-
	(Face Value ₹ 10/- each) (not annualised)	3	Š	3	1	- 8	
	1. Basic	0.08	0.16	0.02	0.54	0.28	0.30
	2.Diluted	0.08	0.15	0.02	0.53	0.27	0.29
	2.Diluted	0.08	0.15	0.02	0.53	0.27	

a) The above is an extract of the detailed format of Quarterly and Nine Months Financial Results filed with the Stock Exchanges on 14th February, 2019 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine Months Financial Results are available on the Companies's website www.duconinfra.co.in and on the Stock Exchange website www.bseindia.

com and www.nseindia.com. b) The Financial results of the Company for the quarter /nine months ended 31st December 2018,have been prepared in accordance with the Indian Accounting Standard (IndAS) as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting

> For Ducon Infratechnologies Ltd. for and on behalf of the Board of Directors

> > Din No: 07144684

Harish Shetty

Consolidated (IFRS)



Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2018

Consolidated (Ind AS)

(₹ in Millions)

Profession (Profession (Prof			Standard (marte)									7								
Memory M					177.0127.102.01				57777577575777	5.00										
No.		(Refer notes below)	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
On the state 1,596.07 1,596.07 1,596.07 1,596.07 1,596.07 1,596.07 1,596.07 1,596.07 1,796			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Description processors 1,000,000 1,0	9	Revenue from operations	1		/	/	1								1	1	/			
Mathematic Resource for Control (1964) 1,000 1,0		(a) Net sales	15,998.97	16,398.12	12,366.78	46,003.77	39,362.08	52,434.15	25,097.79	25,398.57	21,715.05	71,790.02	67,243.39	89,722.32	25,097.79	25,398.57	21,715.05	71,790.02	67,243.39	89,722.32
Both recome		(b) Other operating income	321.39	399.03	934.37	1,172.11	1,618.46	3,007.93	452.66	414.75	321.57	1,229.92	989.15	1,308.38	452.66	414.75	321.57	1,229.92	989.15	1,308.38
R. Boalescenic (1 + 1) 5,779 5,900 5,900 1,972 3,989 17,900 24,900		Total revenue from operations	16,320.36	16,797.15	13,301.15	47,175.88	40,980.54	55,442.08	25,550.45	25,813.32	22,036.62	73,019.94	68,232.54	91,030.70	25,550.45	25,813.32	22,036.62	73,019.94	68,232.54	91,030.70
No. Control methesis consumed 5,365 47 3,969 17 4,346 87 13,916 2 11,911 70 16,480 25 7,316 5 6,032 20 5,051 16 13,922 40 13,951 80 2,951 10 2,951	l l	Other income	(846.41)	2,263.02	371.65	3,072.25	1,360.31	1,799.92			1.000	1,690.80	218.48	914.00	(1,090.24)	1,398.62	(231.64)	1,690.54	218.48	914.00
S. Cont of meterials consumed S. Saber, S. Saber	III	I. Total income (I + II)	15,473.95	19,060.17	13,672.80	50,248.13	42,340.85	57,242.00	24,460.30	27,212.11	21,804.98	74,710.74	68,451.02	91,944.70	24,460.21	27,211.94	21,804.98	74,710.48	68,451.02	91,944.70
Purple P	1\		12702053001550009	A STATE OF THE REAL PROPERTY.		· ·	a management	A 0015030000125050	100000000000000000000000000000000000000		0.000.000.000.00	0.10103.0009993			300000000000000	MONING MAN 1909	000000000000000000000000000000000000000		(1945) 1940 (1946) (1946)	No describerations
Compare in inventions of finished goods , work in reprogress and sord-in-trivial (1.54 p.m.) 1.54 p.m. 1.54				100		10500	6353	0.0	(5)	80	83	18	333	555	88	100	15	100	3.5	2.7
work-in-progress and stock-in-teasing 2,046 3,1326 6,0547 1,15403 1,121.38			908.24	881.14	891.95	2,536.10	2,249.08	2,881.77	2,914.14	2,678.13	1,862.11	8,044.79	5,813.45	7,547.45	2,914.14	2,678.13	1,862.11	8,044.79	5,813.45	7,547.45
Complex personal segments of the personal se			(24.78)	1 134 01	(236 17)	1 549 31	1 121 38	1 397 14	(1.612.05)	97.36	902 44	(1 331 07)	1 377 51	1 337 12	(1.612.05)	97.36	902 44	(1 331 07)	1 377 51	1 337 12
Finance Costs 51.82 069.83 469.96 1.712.05 1.691.07 1.009.96 85.85 2.009.07 1.009.07 1.009.09 1.0						200000000000000000000000000000000000000				0.000	77777	, , ,	10.000000000000000000000000000000000000		1 3 3 3 3 3 3 3 3	100000000000000000000000000000000000000		, , ,	100000000000000000000000000000000000000	100000000000000000000000000000000000000
Production and Amortisation expenses 27.04 28.76 38.90 29.81 79.05 79.05 68.95 78.98 28.94 30.18 78.05			140000000000000000000000000000000000000			0.5000000000000000000000000000000000000		100000000000000000000000000000000000000		100 (0.00)	0.000									
Descriptions Column Colu			100000000000000000000000000000000000000		1907/1908/00	100.000.000		1	72.00.000000	76754755	10.000000000000000000000000000000000000			38 38 36 56	1999 2000					
Total expenses (1) 1,363.567 1,375.68 ol 1,190.10 30.09.98 3,488.97 47.50.29 22.00 1 23.080.00 2,028.97 67.79.4 59.74.28 30.07.60 27.00.45 29.00.00.00.00.00.00.00.00.00.00.00.00.00			600 00000	50000000	500% (60000)						10,000				88.08					
V Port/fives before exceptional internant and tax (iii+V) 1,838 28 3,033.7 1,767.57 1,144.18 9,441.71 1,540.29 4,124.00 1,560.71 2,057.50 1,560.71 1,560.71 2,057.50 1,560.71 1,560.71 2,057.50 1,560.71 1,560.71 2,057.50 1,560.71 1,560			1875-1777-1878		1975.00.0002.50						4.571 (2.571)									
V Exceptional terms (Pietre note 6)) y	1								100000000000000000000000000000000000000	100000000000000000000000000000000000000									
VI To exponents VI To exponent VI VI To exponent VI			1,000,20		500000000000000000000000000000000000000		200000000000000000000000000000000000000	3,541	1,010,20	1.3000000000000000000000000000000000000	10 K (10 K) (10 K (10 K (10 K (10 K (10 K) (10 K (10 K (10 K) (10 K (10 K) (10 K (10 K) (10 K) (10 K (10 K) (10 K) (10 K) (10 K) (10 K (10 K)		and the contraction	11,100.00	1,400.00		300000000000000000000000000000000000000			10,007.00
VIII Tax expenses Current tax Deferred tax			1.838.28		19.000000000000000000000000000000000000	1 1	0.0000000000000000000000000000000000000	9.941.71	1.540.29	1 1000000000000000000000000000000000000	91100000000000	1	992030000000000	11.193.30	1.435.63		200000000000000000000000000000000000000		(0.4500,0000,0000,0000)	10.667.95
Current tax 308.22 1915.64 333.56 2,986.51 1,419.81 2,018.21 2,028.71			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1,100	14,000.00		0,0	1,010.	0,7.00.00	1,000	10,000.	0,100.00		1,100.00	0,000.00	1,000	10,200.20	0,0	10,001.00
X Profit	75.00		309.32	1,915.64	333.56	2,986.51	1,419.81	2,018.21	629.89	2,145.00	529.15	3,891.17	2,295.47	3,256.90	629.89	2,145.00	529.15	3,891.17	2,295.47	3,244.11
Separations (VIII - VIII 1,000 1			(165.26)	(186.17)	(172.56)	(456.63)	(712.81)	(735.11)	(253.01)	(489.10)	(39.87)	(921.26)	(109.27)	(102.30)	(270.93)	(507.71)	(68.41)	(1,006.62)	(183.43)	(318.99)
X Profit(floss) before tax from discontinuing operations: 119.25 222.51 156.03 650.29 553.44 688.56	II.		1 201 00	7.005.75	1 201 70	10 070 45	0.704.00	2.050.04	1 100 44	1 1 10 00	1 047 40	7 000 04	2 500 40	2 200 70	1 270 07	1 242 07	204.50	7.050.70	0.000.40	7.740.00
XI Tax expense of discontinuing operations : 119.25 222.51 156.03 650.29 58.77 73.12	8			9	102000000000000000000000000000000000000					4,140.00	1,047.43	7,633.31	6,522.43	8,038.70	1,076.67	4,049.27	934.58	7,353.73	6,232.46	7,742.83
Current tax			398.25	683.02	509.06	2,028.34	1,805.68	2,246.54	i a	-	-		S.	-	-7	100	10.0	2.5		· ·
Deferred tax			119.25	222.51	156.03	650.29	553.44	688.56		.]]			8	1	4		1			12
Operations (X - XI) Profit (Noss) for the period for continuing and discontinuing operations (X + XII) Profit (Noss) for the period for continuing and discontinuing operations (X + XII) Profit (Noss) for the period for continuing and discontinuing operations (X + XII) Profit (Noss) for the period for continuing and discontinuing operations (X + XII) Profit (Noss) for the period for continuing and discontinuing operations (X + XII) Profit (Noss) for the period for continuing and discontinuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for continuing operations (X + XII) Profit (Noss) for the period for conti			100000000000000000000000000000000000000	0 1994-00000000000					-	-	-	17-	-	-	-/		-/	-	-	-
XIII Profit/(oss) for the period for continuing and discontinuing operations (X × XII) 1,958.71 7,475.59 1,941.16 13,408.24 7,928.35 10,143.47 1,163.41 4,140.00 1,047.43 7,633.31 6,522.43 8,038.70 1,076.67 4,049.27 934.58 7,353.73 6,232.46 7,742.83 XIV Other comprehensive income A (i) Items that will into the reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or loss (iii) income tax relating to items that will be reclassified to profit or lo	X				222.40										1	1	1			
Continuing operations (IX + XII) Continuing operations (IX + XIII) Continuing operations (IX + XIII			264.49	449.84	336.46	1,338.09	1,193.47	1,484.86	-	-	-	-	8-	-	-	-	-	-		-
XIV Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit	XII		1 958 71	7 475 59	1 941 16	13 408 24	7 928 35	10 143 47	1 163 41	4 140 00	1 047 43	7 633 31	6 522 43	8 038 70	1 076 67	4 049 27	934 58	7 353 73	6 232 46	7 742 83
A (i) Hems that will not be reclassified to profit or loss (17.61) (48.45) (11.92) (40.96) (46.61) (10.20) (16.69) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 41.96 (16.89) 3.74 (2.84) 15.15 32.03 (16.96) 3.75 (17.88) 12.94 (17.88) 12.94 (17.88) 12.94 (17.88) 12.94 (17.88) 12.94	$ _{x_{\Gamma}}$		1,000.7	7,470.00	1,541.10	10,400.24	7,020.00	10,140.47	1,100.71	4,140.00	1,047.40	7,000.01	0,022.40	0,000.70	1,070.01	4,045.27	304.00	7,000.70	0,202.40	7,742.00
(ii)Income tax relating to items that will not be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profi	0.00		(17.61)	(48,45)	(11.92)	(40.96)	(46.61)	(10.20)	(16.69)	3.74	(2.84)	15.15	32.03	41.96	(16.69)	3.74	(2.84)	15.15	32.03	41.96
reclassified to profit or loss 6.15 16.93 4.12 14.31 16.13 3.53 6.03 10.15 2.94 7.02 5.90 (3.25) 6.02 1.010 1.045 1.015 1.0			(17.0.,	(40.40)	(11.02)	(40.00)	(40.01)	(10.20)	(10.00)	0	(2.01)	10.10	02.00	41.00	(10.00)	0.17	(2.01)	10.10	32.00	41.00
(ii) Income tax relating to items that will be reclassified to profit or loss reclassified to profit or loss XV Total comprehensive income			6.15	16.93	4.12	14.31	16.13	3.53	6.03	10.15	2.94	7.02	5.90	(3.25)	6.03	10.15	2.94	7.02	5.90	(3.25)
reclassified to profit or loss			82		-1	w/	-/	-	566.06	(600.23)	101.42	(2,759.19)	(267.50)	(778.78)	527.52	(557.92)	62.21	(2,783.90)	(232.25)	(696.17)
XV Total comprehensive income 1,947.25 7,444.07 1,933.36 13,381.59 7,897.87 10,136.80 1,661.89 3,681.33 1,148.95 4,967.04 6,292.86 7,298.63 1,536.61 3,632.91 996.89 4,662.75 6,038.14 7,085.37 7,087.07			1			1 .	.[1 1	(56.92)	127 67		70.75			(56.92)	127 67	A = I	70.75		
XVI Total comprehensive income attributable to:	$ _{\mathbf{x}}$		1 947 25	7 444 07	1 933 36	13 381 59	7 897 87	10 136 80	4.000 (0.000 (0.000))		Francis programation	1-0300000000000000000000000000000000000	200000000000000000000000000000000000000	7 298 63	0.0000000000000000000000000000000000000	proceed block at the re-	15-030.50/90/50	100000000000000000000000000000000000000	100111111111111111111111111111111111111	7 085 37
- Owners of the Company - Owners	χV		1,0-17.20	33331301	1,000.00	10,001.00	7,007.07	10,100.00	1,001.00	0,001.00	1,110.00	1,007.0	0,202.00	7,200.00	1,000.0	0,002.01	300.00	4,002.70	0,000	7,000.0.
XVII Other equity XVII Description of Ref 1/- each) (for continuing operations) (of Ref 1/- each) (for discontinuing operations) (of Ref 1/- each) (for continuing and discontinuing operations)					1 222 22	-/				1 1										
XVIII Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised) Basic EPS (in Rupees) Diluted EPS (in Rupees) 6.00 24.90 5.69 42.78 23.87 30.69 4.12 14.67 3.71 27.05 23.12 28.49 3.82 14.35 3.31 26.06 22.09 27.44 XIX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised) Basic EPS (in Rupees) 0.94 1.59 1.19 4.74 4.23 5.26			1,947.25	7,444.07	1,933.36	13,381.59	7,897.87		1,661.80	3,681.37	1,148.31	4,967.03	6,292.41	500	100	3,632.95	996.25	4,662.74	6,037.69	30
(of Re 1/- each) (not annualised) Basic EPS (in Rupees) (of Re 1/- each) (not annualised) Basic EPS (in Rupees) (of Re 1/- each) (not annualised) Basic EPS (in Rupees) (of Re 1/- each) (not annualised) Basic EPS (in Rupees) (of Re 1/- each) (not annualised)			S=7	S-7	-7	-7	-	1,03,632.24	-	-	-	-	7-	51,352.60	-	()	-	84	-	55,608.37
Basic EPS (in Rupees) 6.00 24.90 5.69 42.78 23.87 30.69 4.12 14.67 3.71 27.05 23.12 28.49 3.82 14.35 3.31 26.06 22.09 27.44 27	XV		1	1	1	1	1		1						1	1	1			
Diluted EPS (in Rupees) 6.00 24.90 5.69 42.78 23.86 30.69 4.12 14.67 3.71 27.05 23.11 28.49 3.82 14.35 3.31 26.06 22.08 27.44			6.00	24.90	5.69	42.78	23.87	30.69	4.12	14.67	3.71	27.05	23.12	28.49	3.82	14.35	3.31	26.06	22.09	27 44
XIX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised) Basic EPS (in Rupees) 0.94 1.59 1.19 4.74 4.23 5.26			1122322 60 00																	
(of Re 1/- each) (not annualised) Basic EPS (in Rupees) Diluted EPS (in Rupees) 0.94 1.59 1.19 4.74 4.23 5.26 - Diluted EPS (in Rupees) 0.94 1.59 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 1.19 4.74 4.23 5.26 4.12 4.23 4.23 4.23 4.23 4.23 4.23 4.23 4.2	XIX		1918/1000		300,000,000	\$190 testes		985,800,800	235265	\$40000000				\$1505000000	55,000	No. 1889 (1987)	575.00			\$50,5700.70
Diluted EPS (in Rupees) 0.94 1.59 1.19 4.74 4.23 5.26 - - - - - - - - -		(of Re 1/- each) (not annualised)	1	1	1	1	1								1	1	1		J	
XX Earning per share (EPS) (for continuing and discontinuing operations) (of Re 1/- each) (not annualised) Basic EPS (in Rupees) 6.94 26.49 6.88 47.52 28.10 35.95 4.12 14.67 3.71 27.05 23.12 28.49 3.82 14.35 3.31 26.06 22.09 27.44		Basic EPS (in Rupees)								-	-		-	1	-	1		1/2	- J	-
discontinuing operations) (of Re 1/- each) (not annualised) (as a continuing operations) (as a continuing operations			0.94	1.59	1.19	4.74	4.23	5.26	-	-	-	00-		(14)	-	8.*/	-		-	
(of Re 1/- each) (not annualised) Basic EPS (in Rupees) 6.94 26.49 6.88 47.52 28.10 35.95 4.12 14.67 3.71 27.05 23.12 28.49 3.82 14.35 3.31 26.06 22.09 27.44	X)		1	1	1	1	1								1	1	1		Į J	
Basic EPS (in Rupees) 6.94 26.49 6.88 47.52 28.10 35.95 4.12 14.67 3.71 27.05 23.12 28.49 3.82 14.35 3.31 26.06 22.09 27.44			1	1	1	1	1								1	1	1		Į J	
			6.94	26.49	6.88	47.52	28.10	35.95	4.12	14.67	3.71	27.05	23.12	28.49	3.82	14.35	3.31	26.06	22.09	27.44
			90,000,000																	

Notes:

- 1. The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
- 2 The above results were reviewed by the Audit Committee at its meeting held on 13 February, 2019 and approved at the meeting of the Board of Directors held on 14 February, 2019.
- 3 The results for the quarter and nine months ended 31 December, 2018 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- On 1 January 2019, the Company completed the transfer of the Company's API business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company.
- During the quarter, the Company bought back U.S.\$86,500,000 in aggregate principal amount of FCCB are outstanding, resulting in gain on extinguishment of liability of Rs. 153.72 million.
- 6 "Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the nine months ended 31 st December, 2018, primarily comprises of net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business). Exceptional items in the consolidated financial results (Ind AS and IFRS) for the nine months ended 31 December 2018 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million."
- Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for nine months ended 31 December, 2018 is not comparable with previous periods presented.
- Effective 1 April, 2018, the Company adopted IND AS 115 or IFRS 15 "Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of IND AS 115 or IFRS 15, as the case may be. 9 The list of subsidiaries as of 31 December, 2018 is provided in Annexure A.
- 10 The Company operates in one reportable business segment i.e., Pharmaceuticals.
- 11 As at 31 December, 2018, pursuant to Employee Stock Options Scheme 2016, 4,59,414 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- 12 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 13 Previous period's figures have been re-grouped/re-classified wherever necessary.

Annexure A

List of entities included in the consolidated financial results for the quarter and nine months ended 31 December 2018

Name of Entities:

Mumbai, February 14, 2019

1) Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K.2) Glenmark Pharmaceuticals S.R.O.4) Glenmark Pharmaceuticals SK, S.R.O.5) Glenmark Pharmaceuti SP z.o.o. 9) Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Generics Inc.) 10) Glenmark Farmaceuticals Mexico, S.A. DE C.V. 14) Glenmark Pharmaceuticals Peru SAC 15) Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia Colombia Ltda., Colombia Colom FZE 21) Glenmark Impex L.L.C 22) Glenmark Philippines Inc. 23) Glenmark Pharmaceuticals (Nigeria) Ltd 24) Glenmark Pharmaceuticals (Australia) Pty Ltd 26) Glenmark South Africa (pty) Ltd 27) Glenmark Pharmaceuticals South Africa (pty) Ltd 28) Glenmark Pharmaceuticals (Australia) Pty Ltd 26) Glenmark Pharmaceuticals (Nigeria) Ltd 28) Glenmark Pharmaceuticals (Australia) Pty Ltd 26) Glenmark Pharmaceuticals (Australia) Pty Ltd 26) Glenmark Pharmaceuticals (Nigeria) Ltd 28) Glenmark Pharmaceuticals (Nigeria) Ltd 27) Glenmark Pharmaceuticals (Nigeria) Ltd 28) Glenmark Pharmaceuticals (Nigeria) Ltd 28) Glenmark Pharmaceuticals (Nigeria) Ltd 27) Glenmark Pharmaceuticals (Nigeria) Ltd 28) Glenmark Pharmaceuticals (Nigeria) Ltd 29) Glenmark Pharmaceutica Pharmaceuticals (Thailand) Co. Ltd 29) Glenmark Pharmaceuticals B.V. (Formerly known as Glenmark Pharmaceuticals Canada Inc.) 30) Glenmark Pharmaceuticals Kenya Ltd 33) Glenmark Pharmaceuticals Canada Inc.) Therapeutics AG 34)Viso Farmaceutica S.L., Spain 35)Glenmark Specialty SA 36)Glenmark Pharmaceuticals Distribution s.r.o. 37)Glenmark Pharmaceuticals Ecuador S.A. 40)Glenmark Pharmaceuticals Singapore Pte. Ltd. 41)Glenmark Biotherapeutics SA 42) Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director

'पन्नी'प्रकरणी सरकारला नोटीस

भूमिका स्पष्ट करण्याचे उच्च न्यायालयाचे आदेश

प्रतिनिधी, मुंबई

सध्या लहान मुले आणि तरुणांमध्ये प्रसिद्ध असलेल्या, परंतु त्याचवेळी त्यांना हिंसक बनवणाऱ्या 'पब्जी' या ऑनलाइन खेळाविरोधात करण्यात आलेल्या जनहित याचिकेप्रकरणी उच्च न्यायालयाने गुरुवारी राज्य आणि केंद्र सरकारला नोटीस बजावत भूमिका स्पष्ट करण्याचे आदेश दिले

लहान मुलेच नव्हे तर मोठ्यांनाही तासन्तास मोबाइलवर खिळवन ठेवणाऱ्या 'पब्जी' या ऑनलाइन खेळावर बंदी घालण्याचे आदेश द्या, अशी मागणी एका ११ वर्षांच्या मुलाने आपल्या आईमार्फत जनहित याचिका करून केली आहे. मुख्य न्यायमूर्ती

बंदी घालण्याची मागणी



या खेळामुळे मुलांच्या मनात हिंसाचाराची भावना वाढत असून सायबर गुन्हेगारीलाही प्रोत्साहन मिळत आहे. त्यामुळे न्यायालयाने राज्य सरकारला या गेमवर बंदी घालण्याचे आदेश द्यावेत. तसेच समाजात हिंसाचार पसरवणाऱ्या

अन्य खेळांवरही देखरेख ठेवण्यासाठी एक विशेष समिती स्थापन करण्याचे आंदेश केंद्र सरकारला द्यावेत, अशी मागणी याचिकेत करण्यात आली आहे.

नरेश पाटील आणि न्यायमूर्ती नितीन प्रयत्न केला. त्यावर आपल्या जामदार यांच्या खंडपीठासमोर पाल्यावर नियंत्रण ठेवण्याची पहिली गुरुवारी याप्रकरणी सुनावणी झाली. आणि मुख्य जबाबदारी ही पालकांची त्या वेळी हा खेळ कसा मुले आणि असले, असे राज्य सरकारच्या वतीने तरुणांना हिंसक बनवत आहे, असे याचिकाकर्त्यांचे वकील तन्वीर याचिकाकर्त्यांनी विरोध केला. तसेच निझाम यांनी न्यायालयाला सांगण्याचा भारतात गुजरात, जम्मू-काश्मीर

आणि इतर काही राज्यांत शाळेच्या आवारात या ऑनलाइन खेळण्यावर बंदी असल्याचे सांगण्यात आले. शिवाय जागतिक आरोग्य संस्थेनेही या खेळाबाबत चिंता व्यक्त केली

लंडनमध्ये तर ऑनलाइन खेळाच्या व्यसनातून सुटकेसाठी व्यसनमुक्ती केंद्रे स्थापन करण्यात आलेली आहेत. या खेळाचा कर्ता असलेल्या चीनने अवध्या दोन आठवड्यांतच या खेळावर बंदी घातली. असेही याचिकाकर्त्यांनी न्यायालयाला सांगितले. सगळ्याची दखल घेत न्यायालयाने राज्य आणि केंद्र सरकारला याप्रकरणी आपली भूमिका स्पष्ट करण्याचे आदेश दिले.

पिश्चम रेल्वेवर लांबपल्ल्याच्या दोन नव्या गाड्या

वांद्रे टर्मिनस-भुसावळ खान्देश आणि इंदूर-खजुराहो एक्स्प्रेस

प्रतिनिधी, मुंबई

प्रवाशांची वाढती मागणी लक्षात घेत पश्चिम रेल्वेने वांद्रे टर्मिनस-भुसावळ खान्देश एक्स्प्रेस आणि इंदूर-खजुराहो एक्स्प्रेस या दोन नव्या लांबपल्ल्याच्या रेल्वेगाड्या सुरू करण्याचा निर्णय घेतला आहे, अशी माहिती पश्चिम रेल्वेचे मुख्य जनसंपर्क अधिकारी रवींद्र भाकर यांनी दिली.

वांद्रे टर्मिनस-भुसावळ खान्देश एक्स्प्रेस ही रेल्वे गाडी क्रमांक १९००३ प्रत्येक शनिवार, सोमवार आणि बुधवारी रात्री ११.५० वाजता वांद्रे टर्मिनस येथून रवाना होईल आणि दुसऱ्या दिवशी १२ वाजता भुसावळ येथे पोहोचेल. भुसावळ-वांद्रे टर्मिनस खान्देश एक्स्प्रेस ही गाडी १९००४



प्रत्येक रविवार, मंगळवार आणि गुरुवारी सायंकाळी ५.४० वाजता भुसावळ येथून रवाना होईल आणि दुसऱ्या दिवशी पहाटे ५.५० वाजता वांद्रे टर्मिनस येथे पोहोचेल.

या रेल्वेगाडीत वातानुकलित द्वितीय आणि तृतीय श्रेणी रायनयान, सर्वसाधारण द्वितीय श्रेणी उपलब्ध असेल. रेल्वेगाडी १९००३ १८ फेब्रुवारीपासन, तर १९००४ १९ फेब्रुवारीपासून सुरू करण्यात येणार

असून या रेल्वेगाड्या बोरिवली, विरार, पालघर, वलसाड, नवसारी, बारडोली, नंदुरबार, दोंडाइचा, सिंदखेडा, नरडाणा, अमळनेर. धरणगाव स्थानकांवर थांबतील.

या ट्रेनला भुसावळ रेल्वे स्थानकात १६ फेब्रुवारी रोजी दुपारी ३ वाजता भुसावळ-वांद्रे टर्मिनस खान्देश एक्स्प्रेसला हिरवा दाखविण्यात येणार आहे. ही रेल्वे

वाजता वांद्रे टर्मिनस येथे पोहोचेल. येत्या १७ फेब्रुवारीपासून सुरू करण्यात येणारी इंदूर- खजुराहो एक्स्प्रेस दर सोमवार, बुधवार, शनिवार आणि रविवारी इंदूर येथून दुपारी ३.५५ वाजता सोडण्यात येणार असून ती दुसऱ्या दिवशी सकाळी ६ वाजता खजुराहो येथे पोहेचेल. तर

गाडी दुसऱ्या दिवशी मध्यरात्री १.१०

खजुराहो-इंदूर एक्स्प्रेस खजुराहो येथून दर रविवार, मंगळवार, शुक्रवार आणि रानिवारी रात्री ११.३० वाजता सोडण्यात येणार असून ती दुसऱ्या दिवशी ३.५० वाजता इंदर येथे पोहोचेल. ही गाडी उज्जैन, संत हिरदारामनगर, साँची, विदिशा, बीना, ललितपूर, टीकमगढ, खडगपूर, छतरपूर या रेल्वे स्थानकांवर

थांबेल.

glenmark PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2018

(₹	in	Mill	ions

		Standalone (Ind A				d AS)			Consolidated (Ind AS)							Consolidated (IFRS)						
	Particulars (Refer notes below)	Quarter ended 31-12-2018 (Unaudited)		Quarter ended 31-12-2017 (Unaudited)	ended 31-12-2018		Year ended 31-03-2018 (Audited)		Quarter ended 30-09-2018 (Unaudited)		ended 31-12-2018	Nine Months ended 31-12-2017 (Unaudited)	Year ended 31-03-2018 (Audited)		Quarter ended 30-09-2018 (Unaudited)	Quarter ended 31-12-2017 (Unaudited)	STATE OF THE STATE	ended 31-12-2017	Year ended 31-03-2018 (Audited)			
I.	Revenue from operations																					
	(a) Net sales	15,998.97	16,398.12	12,366.78	46,003.77	39,362.08	52,434.15	25,097.79	25,398.57	21,715.05	71,790.02	67,243.39	89,722.32	25,097.79	25,398.57	21,715.05	71,790.02	67,243.39	89,722.32			
Ш	(b) Other operating income	321.39	399.03	934.37	1,172.11	1,618.46	3,007.93	452.66	414.75	321.57	1,229.92	989.15	1,308.38	452.66	414.75	321.57	1,229.92	989.15	1,308.38			
Ш	Total revenue from operations	16,320.36	16,797.15	13,301.15	47,175.88	40,980.54	55,442.08	25,550.45	25,813.32	22,036.62	73,019.94	68,232.54	91,030.70	25,550.45	25,813.32	22,036.62	73,019.94	68,232.54	91,030.70			
II.	Other income	(846.41)	2,263.02	371.65	3,072.25	1,360.31	1,799.92	(1,090.15)	1,398.79	(231.64)	1,690.80	218.48	914.00	(1,090.24)	1,398.62	(231.64)	1,690.54	218.48	914.00			
III.	Total income (I + II)	15,473.95	19,060.17	13,672.80	50,248.13	42,340.85	57,242.00	24,460.30	27,212.11	21,804.98	74,710.74	68,451.02	91,944.70	24,460.21	27,211.94	21,804.98	74,710.48	68,451.02	91,944.70			
IV.	Expenses	7000.0000.0000.0000	NO. 100 CO. 10	5-0000000000000000000000000000000000000		S7628-976 N-07-9665		2010/01/2012/01/2012			110000,100000000	000000000000000000000000000000000000000		100110000000000000000000000000000000000	100000000000000000000000000000000000000	0.0000000000000000000000000000000000000		500000000000000000000000000000000000000	ACCES - 12-10 - 12-10-10-10-1			
Ш	Cost of materials consumed	5,365.47	3,859.17	4,346.87	13,309.62	11,911.70	16,480.25	7,318.05	6,032.60	5,051.16	18,302.48	15,351.68	21,501.10	7,318.05		(8)	18,302.48	15,351.68	21,501.10			
Ш	b. Purchase of stock-in-trade	908.24	881.14	891.95	2,536.10	2,249.08	2,881.77	2,914.14	2,678.13	1,862.11	8,044.79	5,813.45	7,547.45	2,914.14	2,678.13	1,862.11	8,044.79	5,813.45	7,547.45			
Ш	c. Changes in inventories of finished goods,	(04.70)	1 101 01	(000.47)	4 5 40 04	1 101 00	1 007 11	(4.040.05)	07.00	000.44	(4 004 07)	1 077 51	1 007 10	(4.040.05)	07.00	000.44	(4 004 07)	1.077.51	1 007 10			
Ш	work-in-progress and stock-in-trade	(24.78)		(236.17)	1,549.31	1,121.38		(1,612.05)	97.36	902.44	**********			(1,612.05)	97.36		(1,331.07)	1,377.51	1,337.12			
Ш	d. Employee benefits expense e. Finance Costs	2,320.86	3,123.98	2,222.01	7,457.54	6,909.79		5,030.81	6,058.95	4,659.42		14,075.68	18,718.41	5,030.81	6,058.95	100 (000)	15,614.85	14,075.68 2,111.79	18,718.41			
Ш	f. Depreciation and Amortisation expense	551.82 257.04	608.53 269.23	469.99 238.64	1,712.06 799.31	1,401.76 720.55		885.35 831.01	851.27 824.50	704.74 753.84	100000000000000000000000000000000000000	17.0 X 4.0 X 4.0 X 5.0 X	2,855.67 3,018.76	885.35 935.58		704.74 895.18		2,646.43	2,855.67 3,540.67			
Ш	f. Other expenses	4,257.02		3,973.81	11,736.01	10,584.71		7,552.70	6,545.22	6,334.56	18	18,728.84	25,772.89				20,172.20	18,729.98	25,776.33			
Ш	Total expenses (IV)	13,635.67	13,756.80		39,099.95		47,300.29	22,920.01	23,088.03	20,268.27	27/5/2012/01/01	59,742.39				38,037,036	66,144.02		81,276.75			
Πv	Profit/(loss) before exceptional items and tax (III-IV)	1,838.28		1,765.70				1,540.29	4,124.08	1,536.71	8,931.40					1,395.32			10,667.95			
	Exceptional items (Refer note 6)	1,030.20	(3,451.85)		(3,451.85)		5,541.71	1,540.25	(1,671.82)	1,000.71	(1,671.82)	0,700.03	11,193.30	1,400.00	(1,671.82)	1,353.32	(1,671.82)	0,344.50	10,007.95			
	Profit/(loss) before tax (V - VI)	1,838.28		1,765.70	1.700		9,941.71	1,540.29	5,795.90	1,536.71	10,603.22	8,708.63	11,193.30	1,435.63	300	1,395.32	1310	8,344.50	10,667.95			
9.00	Tax expense :	1,000.20	0,755.22	1,700.70	14,000.00	7,441.00	3,341.71	1,040.20	3,733.30	1,000.71	10,000.22	0,700.00	11,130.00	1,400.00	5,000.50	1,000.02	10,200.20	0,044.00	10,007.55			
*	Current tax	309.32	1,915.64	333.56	2,986.51	1,419.81	2,018.21	629.89	2,145.00	529.15	3,891.17	2,295.47	3,256.90	629.89	2,145.00	529.15	3,891.17	2,295.47	3,244.11			
Ш	Deferred tax	(165.26)	(186.17)	(172.56)	(456.63)	(712.81)	(735.11)	(253.01)	(489.10)	(39.87)	(921.26)	(109.27)	(102.30)	(270.93)		(68.41)	(1,006.62)	(183.43)	(318.99)			
IX	Profit/(loss) for the period from continuing			101121011111				277722222	7502.002.003	20000000000									23-8332002			
Ш	operations (VII - VIII)	1,694.22	122	1,604.70	12,070.15	18	32.5	1,163.41	4,140.00	1,047.43	7,633.31	6,522.43	8,038.70	1,076.67	4,049.27	934.58	7,353.73	6,232.46	7,742.83			
	Profit/(loss) before tax from discontinuing operations Tax expense of discontinuing operations:	398.25	683.02	509.06	2,028.34	1,805.68	2,246.54	-	-		-	-	-		-	-		-	-			
^'	Current tax	119.25	222.51	156.03	650.29	553.44	688.56					-	_				0.4	20-	80+			
Ш	Deferred tax	14.51	10.67	16.57	39.96		73.12	-	-	-	-	-	-	-	-	-	-	-	-			
XII	Profit/(loss) for the period from discontinuing		C1000 THE LOCATION		0.0 D. 0.0 D		A THE SECOND AND ADDRESS															
Sec	operations (X - XI)	264.49	449.84	336.46	1,338.09	1,193.47	1,484.86	-	-	-	-	-	-	-		-		-	-			
XIII	Profit/(loss) for the period for continuing and	1,958.71	7,475.59	1 0/1 16	13,408.24	7,928.35	10 142 47	1,163.41	4,140.00	1,047.43	7,633.31	6,522.43	8,038.70	1,076.67	4,049.27	934.58	7 252 72	6 222 46	7 7/2 92			
	discontinuing operations (IX + XII) Other comprehensive income	1,956.71	7,475.59	1,941.16	13,400.24	7,820.33	10,143.47	1,103.41	4,140.00	1,047.43	7,000.01	0,322.43	0,030.70	1,076.67	4,049.27	934.30	7,353.73	6,232.46	7,742.83			
^''	A (i) Items that will not be reclassified to profit or loss	(17.61)	(48.45)	(11.92)	(40.96)	(46.61)	(10.20)	(16.69)	3.74	(2.84)	15.15	32.03	41.96	(16.69)	3.74	(2.84)	15.15	32.03	41.96			
Ш	(ii)Income tax relating to items that will not be	(17.01)	(40.45)	(11.52)	(40.30)	(40.01)	(10.20)	(10.03)	5.74	(2.04)	15.15	32.03	41.50	(10.03)	3.74	(2.04)	15.15	32.00	41.30			
Ш	reclassified to profit or loss	6.15	16.93	4.12	14.31	16.13	3.53	6.03	10.15	2.94	7.02	5.90	(3.25)	6.03	10.15	2.94	7.02	5.90	(3.25)			
Ш	B (i) Items that will be reclassified to profit or loss	-		85	-	85	0.7	566.06	(600.23)	101.42	(2,759.19)	(267.50)	(778.78)	527.52	(557.92)	62.21	(2,783.90)	(232.25)	(696.17)			
Ш	 (ii) Income tax relating to items that will be reclassified to profit or loss 		113	1755		900		(56.92)	127.67		70.75			(56.92)	127.67		70.75		100			
VV	Total comprehensive income	1,947.25	7,444.07	1,933.36	13,381.59	7 907 97	10,136.80	1,661.89	3,681.33	1,148.95	Terrent Personal	6,292.86	7,298.63		3,632.91	996.89		6,038.14	7,085.37			
XVI		1,047.20	7,444.07	1,500.00	10,001.09	7,007.07	10,130.00	1,001.09	0,001.00	1,140.93	4,507.04	0,232.00	7,250.03	1,000.01	3,032.91	330.03	4,002.73	0,030.14	7,000.07			
13/250	- Non-controlling interests	sungara a	-				-	0.09	(0.04)	0.64	0.01	0.45	0.92	0.09	1 1	0.64	0.01	0.45	0.92			
<u></u>	- Owners of the Company	1,947.25	7,444.07	1,933.36	13,381.59	7,897.87		1,661.80	3,681.37	1,148.31	4,967.03	6,292.41	7,297.71	1,536.52	3,632.95	996.25	4,662.74	6,037.69	7,084.45			
	Other equity		-		-	-	1,03,632.24		-	-	-	-	51,352.60		-			-	55,608.37			
XVIII	Earning per share (EPS) (for continuing operations)																					
Ш	(of Re 1/- each) (not annualised) Basic EPS (in Rupees)	6.00	24.90	5.69	42.78	23.87	30.69	4.12	14.67	3.71	27.05	23.12	28.49	3.82	14.35	3.31	26.06	22.09	27.44			
Ш	Diluted EPS (in Rupees)	6.00		5.69	42.78	23.86	30.69	4.12	14.67	3.71	27.05	23.11	28.49			3.31	26.06	22.08	27.44			
XIX	Earning per share (EPS)(for discontinuing operations)	100000000000000000000000000000000000000		1955.000	277100	1551-1511	96.376.57	0310700			12503.36-65	PRODUCTION.		5000	(0.000000000000000000000000000000000000	1985350						
100000	(of Re 1/- each) (not annualised)																					
П	Basic EPS (in Rupees)	0.94	1.59		4.74				-	-	-	0/2	-	-								
1/4/2014	Diluted EPS (in Rupees)	0.94	1.59	1.19	4.74	4.23	5.26		-	-	-	-	-	1		-		-	-			
ll ^{xx}	Earning per share (EPS) (for continuing and discontinuing operations)																		- 1			
Ш	(of Re 1/- each) (not annualised)																		- 1			
Ш	Basic EPS (in Rupees)	6.94	26.49	6.88	47.52	28.10	35.95	4.12	14.67	3.71	27.05	23.12	28.49	3.82	14.35	3.31	26.06	22.09	27.44			
	Diluted EPS (in Rupees)	6.94	26.49					4.12	14.67	3.71	27.05		28.49		14.35	3.31	26.06	22.08	27.44			
		7.																				

Notes:

- 1. The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
- 2 The above results were reviewed by the Audit Committee at its meeting held on 13 February, 2019 and approved at the meeting of the Board of Directors held on 14 February, 2019.
- 3 The results for the guarter and nine months ended 31 December, 2018 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- 4 On 1 January 2019, the Company completed the transfer of the Company's API business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company.
- 5 During the quarter, the Company bought back U.S.\$86,500,000 in aggregate principal amount of the Foreign Currency Convertible Bonds (FCCB). As of 31 December, 2018, U.S.\$113,500,000 in aggregate principal amount of FCCB are outstanding, resulting in gain on extinguishment of liability
- 6 "Exceptional item: Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the nine months ended 31 st December, 2018, primarily comprises of net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business). Exceptional items in the consolidated financial results (Ind AS and IFRS) for the nine months ended 31 December 2018 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million."
- 7 Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018
- includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for nine months ended 31 December, 2018 is not comparable with previous periods presented. 8 Effective 1 April, 2018, the Company adopted IND AS 115 or IFRS 15 "Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of IND AS 115 or IFRS 15, as the case may be.
- 9 The list of subsidiaries as of 31 December, 2018 is provided in Annexure A.
- 10 The Company operates in one reportable business segment i.e., Pharmaceuticals,
- 11 As at 31 December, 2018, pursuant to Employee Stock Options Scheme 2016, 4,59,414 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- 12 Diluted EPS has been computed considering the effect of conversion of ESOPs. 13 Previous period's figures have been re-grouped/re-classified wherever necessary.

Annexure A

List of entities included in the consolidated financial results for the guarter and nine months ended 31 December 2018

1) Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K.2) Glenmark Pharmaceuticals S.R.O.4) Glenmark Pharmaceuticals S.R.O.4) Glenmark Pharmaceuticals S.R.O.5) Glenmark Pharmaceuti SP z.o.o. 9) Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Generics Inc.) 10) Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14) Glenmark Pharmaceuticals Peru SAC 15) Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Pharmaceuticals Inc.) 10) Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Pharmaceuticals Inc.) 11) Glenmark Pharmaceuticals Inc.) 12) Glenmark Pharmaceuticals Inc.) 13) Glenmark Pharmaceuticals Inc.) 13) Glenmark Pharmaceuticals Inc.) 14) Glenmark Pharmaceuticals Inc.) 15) Glenmark Pharmaceuticals Inc.) 15) Glenmark Pharmaceuticals Inc.) 15) Glenmark Pharmaceuticals Inc.) 16) Glenmark Pharmaceuticals Inc.) 16) Glenmark Pharmaceuticals Inc.) 17) Glenmark Pharmaceuticals Inc.) 17) Glenmark Pharmaceuticals Inc.) 17) Glenmark Pharmaceuticals Inc.) 18) Glenmark Pharmaceuticals Inc.) 18) Glenmark Pharmaceuticals Inc.) 19) Glenmark Pharmaceuti Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia (Formerly known as Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia (Formerly known as Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia (Formerly known as Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia (Formerly known as Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia (Formerly known as Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia (Formerly known as Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia) 16) Glenmark Pharmaceuticals Colombia) 17) Glenmark Pharmaceuticals Colombia) 17) Glenmark Pharmaceuticals Colombia) 18) Glenmark Pharmaceuticals Colombia) 18) Glenmark Pharmaceuticals Colombia) 19) Glenmark Pharmaceuticals Colombi FZE 21) Glenmark Impex L.L.C 22) Glenmark Philippines Inc. 23) Glenmark Pharmaceuticals (Nigeria) Ltd 24) Glenmark Pharmaceuticals (Australia) Pty Ltd 26) Glenmark South Africa (pty) Ltd 27) Glenmark Pharmaceuticals South Africa (pty) Ltd 28) Glenmark Pharmaceuticals (Australia) Pty Ltd 26) Glenmark Pharmaceuticals (Pharmaceuticals South Africa (pty) Ltd 28) Glenmark Pharmaceuticals (Pharmaceuticals South Africa (pty) Ltd 27) Glenmark Pharmaceuticals (Pharmaceuticals South Africa (pty) Ltd 28) Glenmark Pharmaceuticals (Pharmaceuticals South Africa (pty) Ltd 27) Glenmark Pharmaceuticals (Pharmaceuticals South Africa (pty) Ltd 28) Glenmark Pharmaceuticals (Pharmaceuticals Pharmaceuticals Pharmaceuticals Pharmaceuticals (Pharmaceuticals Pharmaceuticals Pharmaceuticals Pharmaceuticals Pharmaceuticals Pharmaceuticals (Pharmaceuticals Pharmaceuticals Pharmac Pharmaceuticals (Thailand) Co. Ltd 29) Glenmark Pharmaceuticals B.V. (Formerly known as Glenmark Pharmaceuticals Canada Inc.) 32) Glenmark Pharmaceuticals Kenya Ltd 33) Glenmark Pharmaceuticals Canada Inc. (formerly known as Glenmark Pharmaceuticals Canada Inc.) 32) Glenmark Pharmaceuticals Kenya Ltd 33) Glenmark Pharmaceuticals Canada Inc.) 33) Glenmark Pharmaceuticals Canada Inc.) 34) Glenmark Pharmaceuticals Canada Inc.) 35) Glenmark Pharmaceuticals Canada Inc.) 36) Glenmark Pharmaceuticals Canada Inc.) 37) Glenmark Pharmaceuticals Canada Inc.) 37) Glenmark Pharmaceuticals Canada Inc.) 37) Glenmark Pharmaceuticals Canada Inc.) 38) Glenmark Pharmaceuticals Canada Inc.) 39) Glenmark Pharmaceu Therapeutics AG 34) Viso Farmaceutica S.L., Spain 35) Glenmark Pharmaceuticals Distribution s.r.o. 37) Glenmark Pharmaceuticals Ecuador S.A. 40) Glenmark Pharmaceuticals Singapore Pte. Ltd. 41) Glenmark Biotherapeutics SA 42) Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

> For and on behalf of the Board of Directors Glenn Saldanha Chairman & Managing Director

Mumbai, February 14, 2019